Qian W, Wang L, Li P, Hu Y, Wang Q, Yi K, et al. Efficiency and Tolerability of Induction and Consolidation Therapy with Arsenic Trioxide/Bortezomib/Ascorbic Acid/Dexamethasone (ABCD) Regimen Compared to Bortezomib/Dexamethasone (BD) Regimen in Newly Diagnosed Myeloma Patients. Cancer Manag Res. 2020;12:431-441 pubmed publisher

Valdez B, Li Y, Murray D, Liu Y, Nieto Y, Bashir Q, et al. Panobinostat and venetoclax enhance the cytotoxicity of gemcitabine, busulfan, and melphalan in multiple myeloma cells. Exp Hematol. 2020;81:32-41 pubmed publisher

Finazzi M, Boschini C, Craddock C, Rambaldi A, Ward J, Malladi R. Characteristics of graft-versus-host disease occurring after alemtuzumab-containing allogeneic stem cell transplants: incidence, organ involvement, risk factors and survival. Br J Haematol. 2020;188:550-559 pubmed publisher

Tabata M, Tsubaki M, Takeda T, Tateishi K, Maekawa S, Tsurushima K, et al. Inhibition of HSP90 overcomes melphalan resistance through downregulation of Src in multiple myeloma cells. Clin Exp Med. 2020;20:63-71 pubmed publisher

Guadagni S, Fiorentini G, De Simone M, Masedu F, Zoras O, Mackay A, et al. Precision oncotherapy based on liquid biopsies in multidisciplinary treatment of unresectable recurrent rectal cancer: a retrospective cohort study. J Cancer Res Clin Oncol. 2020;146:205-219 pubmed publisher

Teras J, Mägi A, Teras M, Pata P, Teras R, Randhawa N, et al. Soft Tissue Cancer Management: Isolated Limb Infusion for Sarcoma. Visc Med. 2019;35:373-379 pubmed publisher

Faict S, Oudaert I, D Auria L, Dehairs J, Maes K, Vlummens P, et al. The Transfer of Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma. Cancers (Basel). 2019;11: pubmed publisher

Srisongkram T, Weerapreeyakul N, Kärkkäinen J, Rautio J. Role of L-Type Amino Acid Transporter 1 (LAT1) for the Selective Cytotoxicity of Sesamol in Human Melanoma Cells. Molecules. 2019;24: pubmed publisher

Kanakkanthara A, Huntoon C, Hou X, Zhang M, Heinzen E, O Brien D, et al. ZC3H18 specifically binds and activates the BRCA1 promoter to facilitate homologous recombination in ovarian cancer. Nat Commun. 2019;10:4632 pubmed publisher

Sharpley F, Petrie A, Mahmood S, Sachchithanantham S, Lachmann H, Gillmore J, et al. A 24-year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United Kingdom. Br J Haematol. 2019;187:642-652 pubmed publisher

Pocasap P, Weerapreeyakul N, Thumanu K. Alyssin and Iberin in Cruciferous Vegetables Exert Anticancer Activity in HepG2 by Increasing Intracellular Reactive Oxygen Species and Tubulin Depolymerization. Biomol Ther (Seoul). 2019;27:540-552 pubmed publisher

Klager S, Lacouture M, Hannum M, Devlin S, Maloy M, Pulitzer M, et al. Drugs as a Frequent Cause of Acute Rash in Patients after CD34+-Selected Peripheral Blood Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019;25:2172-2180 pubmed publisher

Harrington K, Freeman D, Kelly B, Harper J, Soria J. Optimizing oncolytic virotherapy in cancer treatment. Nat Rev Drug Discov. 2019;18:689-706 pubmed publisher

Bashir Q, Chamoun K, Milton D, Khan M, Ahmed S, Mehta R, et al. Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years. Leuk Lymphoma. 2019;60:3536-3543 pubmed publisher

Tacconi E, Badie S, De Gregoriis G, Reisländer T, Lai X, Porru M, et al. Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance. EMBO Mol Med. 2019;11:e9982 pubmed publisher

Kucab J, Zou X, Morganella S, Joel M, Nanda A, Nagy E, et al. A Compendium of Mutational Signatures of Environmental Agents. Cell. 2019;177:821-836.e16 pubmed publisher

Abruzzese M, Bilotta M, Fionda C, Zingoni A, Soriani A, Petrucci M, et al. The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors. Cell Death Dis. 2019;10:324 pubmed publisher

Grueneisen J, Schaarschmidt B, Demircioglu A, Chodyla M, Martin O, Bertram S, et al. 18F-FDG PET/MRI for Therapy Response Assessment of Isolated Limb Perfusion in Patients with Soft-Tissue Sarcomas. J Nucl Med. 2019;60:1537-1542 pubmed publisher

Gourzones C, Bellanger C, Lamure S, Gadacha O, de Paco E, Vincent L, et al. Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells. Cancers (Basel). 2019;11: pubmed publisher

Bashir Q, Thall P, Milton D, Fox P, Kawedia J, Kebriaei P, et al. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol. 2019;6:e266-e275 pubmed publisher

Tabatabaei S, Derbali R, Yang C, Superstein R, Hamel P, Chain J, et al. Co-delivery of miR-181a and melphalan by lipid nanoparticles for treatment of seeded retinoblastoma. J Control Release. 2019;298:177-185 pubmed publisher

Assi T, Cavalcanti A, Le Cesne A, Faron M, Honart J, Hadiji A, et al. Neoadjuvant isolated limb perfusion in newly diagnosed untreated patients with locally advanced soft tissue sarcomas of the extremities: the Gustave Roussy experience. Clin Transl Oncol. 2019;: pubmed publisher

Belgrano V, Pettersson J, Nilsson J, Mattsson J, Katsarelias D, Olofsson Bagge R. Response and Toxicity of Repeated Isolated Limb Perfusion (re-ILP) for Patients With In-Transit Metastases of Malignant Melanoma. Ann Surg Oncol. 2019;26:1055-1062 pubmed publisher

Rule S, Cook G, Russell N, Hunter A, Robinson S, Morley N, et al. Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma. Br J Haematol. 2019;184:999-1005 pubmed publisher

Schäfer J, Burhenne J, Weiss J, Theile D. Elucidating the beneficial effects of melphalan, adriamycin, and corticoids in combination with bortezomib against multiple myeloma in vitro. Naunyn Schmiedebergs Arch Pharmacol. 2019;392:461-466 pubmed publisher

Brierley C, Jones F, Hanlon K, Peniket A, Hatton C, Collins G, et al. Impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned-alemtuzumab allogeneic haematopoietic stem cell transplantation for patients with mature lymphoid malignancies. Br J Haematol. 2019;184:547-557 pubmed publisher

Mashimo K, Tsubaki M, Takeda T, Asano R, Jinushi M, Imano M, et al. RANKL-induced c-Src activation contributes to conventional anti-cancer drug resistance and dasatinib overcomes this resistance in RANK-expressing multiple myeloma cells. Clin Exp Med. 2019;19:133-141 pubmed publisher

Li N, Lopez M, Linares M, Kumar S, Oliva S, Martinez Lopez J, et al. Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia. Clin Cancer Res. 2019;25:369-377 pubmed publisher

van de Donk N, van der Holt B, Minnema M, Vellenga E, Croockewit S, Kersten M, et al. Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial. Lancet Haematol. 2018;5:e479-e492 pubmed publisher

Reese M, Knapp D, Anderson K, Mund J, Case J, Jones D, et al. In vitro effect of chlorambucil on human glioma cell lines (SF767 and U87-MG), and human microvascular endothelial cell (HMVEC) and endothelial progenitor cells (ECFCs), in the context of plasma chlorambucil concentrations in tumor-bearing dogs. PLoS ONE. 2018;13:e0203517 pubmed publisher

Gudmundsson B, Thormar H, Sigurdsson A, Dankers W, Steinarsdottir M, Hermanowicz S, et al. Northern lights assay: a versatile method for comprehensive detection of DNA damage. Nucleic Acids Res. 2018;46:e118 pubmed publisher

Stevenson M, Hoekstra H, Song W, Suurmeijer A, Been L. Histopathological tumor response following neoadjuvant hyperthermic isolated limb perfusion in extremity soft tissue sarcomas: Evaluation of the EORTC-STBSG response score. Eur J Surg Oncol. 2018;44:1406-1411 pubmed publisher

Bentley R, Thomovsky S, Miller M, Knapp D, Cohen Gadol A. Canine (Pet Dog) Tumor Microsurgery and Intratumoral Concentration and Safety of Metronomic Chlorambucil for Spontaneous Glioma: A Phase I Clinical Trial. World Neurosurg. 2018;116:e534-e542 pubmed publisher

Lam C, Ferguson I, Mariano M, Lin Y, Murnane M, Liu H, et al. Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. Haematologica. 2018;103:1218-1228 pubmed publisher

Anunobi R, Boone B, Cheh N, Tang D, Kang R, Loux T, et al. Extracellular DNA promotes colorectal tumor cell survival after cytotoxic chemotherapy. J Surg Res. 2018;226:181-191 pubmed publisher

Tretiakova D, Onishchenko N, Boldyrev I, Mikhalyov I, Tuzikov A, Bovin N, et al. Influence of stabilizing components on the integrity of antitumor liposomes loaded with lipophilic prodrug in the bilayer. Colloids Surf B Biointerfaces. 2018;166:45-53 pubmed publisher

Stevenson M, Seinen J, Pras E, Brouwers A, van Ginkel R, van Leeuwen B, et al. Hyperthermic isolated limb perfusion, preoperative radiotherapy, and surgery (PRS) a new limb saving treatment strategy for locally advanced sarcomas. J Surg Oncol. 2018;117:1447-1454 pubmed publisher

Abate M, Paioli A, Cammelli S, Cesari M, Longhi A, Palmerini E, et al. Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma. Bone Marrow Transplant. 2018;53:591-599 pubmed publisher

Landini I, Lapucci A, Pratesi A, Massai L, Napoli C, Perrone G, et al. Selection and characterization of a human ovarian cancer cell line resistant to auranofin. Oncotarget. 2017;8:96062-96078 pubmed publisher

Campbell J, Heaney J, Pandya S, Afzal Z, Kaiser M, Owen R, et al. Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study. Lancet Haematol. 2017;4:e584-e594 pubmed publisher

Chai R, McDonald M, Terry R, Kovacic N, Down J, Pettitt J, et al. Melphalan modifies the bone microenvironment by enhancing osteoclast formation. Oncotarget. 2017;8:68047-68058 pubmed publisher

Jeon H, Kim D, Choi M, Kang S, Kim J, Kim S, et al. Targeted Cancer Therapy Using Fusion Protein of TNF? and Tumor-Associated Fibronectin-Specific Aptide. Mol Pharm. 2017;14:3772-3779 pubmed publisher

Rojas E, Corchete L, San Segundo L, Martinez Blanch J, Codoñer F, Paíno T, et al. Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma. Clin Cancer Res. 2017;23:6602-6615 pubmed publisher

Yang H, Zheng Y, Zhang Y, Cao Z, Jiang Y. Mesenchymal stem cells derived from multiple myeloma patients protect against chemotherapy through autophagy-dependent activation of NF-κB signaling. Leuk Res. 2017;60:82-88 pubmed publisher

Mei M, Cao T, Chen L, Song J, Siddiqi T, Cai J, et al. Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab. Biol Blood Marrow Transplant. 2017;23:1861-1869 pubmed publisher

Yang Q, Tripathy A, Yu W, Eberhart C, Asnaghi L. Hypoxia inhibits growth, proliferation, and increases response to chemotherapy in retinoblastoma cells. Exp Eye Res. 2017;162:48-61 pubmed publisher

Borriello L, Nakata R, Sheard M, Fernandez G, Sposto R, Malvar J, et al. Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells. Cancer Res. 2017;77:5142-5157 pubmed publisher

Salvador D, Soave D, Sacono N, de Castro E, Silva G, E Silva L, et al. Effect of photobiomodulation therapy on reducing the chemo-induced oral mucositis severity and on salivary levels of CXCL8/interleukin 8, nitrite, and myeloperoxidase in patients undergoing hematopoietic stem cell transplantation: a randomized clinic. Lasers Med Sci. 2017;32:1801-1810 pubmed publisher

Berry J, Bechtold M, Shah S, Zolfaghari E, Reid M, Jubran R, et al. Not All Seeds Are Created Equal: Seed Classification Is Predictive of Outcomes in Retinoblastoma. Ophthalmology. 2017;124:1817-1825 pubmed publisher

Szalat R, Samur M, Fulciniti M, Lopez M, Nanjappa P, Cleynen A, et al. Nucleotide excision repair is a potential therapeutic target in multiple myeloma. Leukemia. 2017;: pubmed publisher

Saijo R, Sekiya H, Tamai E, Kurihara K, Maki J, Sakagami H, et al. A Novel Methodology for Synthesis of 1,5,6-Trisubstituted 2(1H)-Pyrazinones of Biological Interest. Chem Pharm Bull (Tokyo). 2017;65:365-372 pubmed publisher

Glazer E, Zager J. Chemosaturation With Percutaneous Hepatic Perfusion in Unresectable Hepatic Metastases. Cancer Control. 2017;24:96-101 pubmed

Lin L, Wu M, Pidugu V, Ho I, Su T, Lee T. P-glycoprotein attenuates DNA repair activity in multidrug-resistant cells by acting through the Cbp-Csk-Src cascade. Oncotarget. 2017;8:45072-45087 pubmed publisher

Burton J, Knych H, Stanley S, Rebhun R. Potency and stability of compounded formulations of chlorambucil, melphalan and cyclophosphamide. Vet Comp Oncol. 2017;15:1558-1563 pubmed publisher

Kiratli H, Koç İ, Varan A, Akyuz C. Intravitreal chemotherapy in the management of vitreous disease in retinoblastoma. Eur J Ophthalmol. 2017;27:423-427 pubmed publisher

Bespalov V, Vyshinskaya E, Vasil eva I, Semenov A, Maidin M, Barakova N, et al. Comparative Study of Antitumor Efficiency of Intraperitoneal and Intravenous Cytostatics in Experimental Rats with Disseminated Ovarian Cancer. Bull Exp Biol Med. 2017;162:383-386 pubmed publisher

Zatula A, Dikic A, Mulder C, Sharma A, Vågbø C, Sousa M, et al. Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia. Oncotarget. 2017;8:19427-19442 pubmed publisher

Ryu J, Koh Y, Park H, Kim D, Kim D, Byun J, et al. Highly Expressed Integrin-α8 Induces Epithelial to Mesenchymal Transition-Like Features in Multiple Myeloma with Early Relapse. Mol Cells. 2016;39:898-908 pubmed publisher

Strese S, Hassan S, Velander E, Haglund C, Höglund M, Larsson R, et al. In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia. Oncotarget. 2017;8:6341-6352 pubmed publisher

Antonangeli F, Soriani A, Ricci B, Ponzetta A, Benigni G, Morrone S, et al. Natural killer cell recognition of in vivo drug-induced senescent multiple myeloma cells. Oncoimmunology. 2016;5:e1218105 pubmed

Jakubikova J, Cholujova D, Hideshima T, Gronesova P, Soltysova A, Harada T, et al. A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications. Oncotarget. 2016;7:77326-77341 pubmed publisher

Suzuki K, Yano S, Nishiwaki K, Sano K, Shimada T, Yahagi Y, et al. Clinical significance of granule-containing myeloma cells in patients with newly diagnosed multiple myeloma. Cancer Med. 2016;5:3051-3058 pubmed publisher

Cao J, Lin G, Gong Y, Pan P, Ma Y, Huang P, et al. DNA-PKcs, a novel functional target of acriflavine, mediates acriflavine's p53-dependent synergistic anti-tumor efficiency with melphalan. Cancer Lett. 2016;383:115-124 pubmed publisher

Wang C, He Z, Shi Y, Zhang L, Chen Y, Chen Z, et al. Low-dose lenalidomide and dexamethasone combination treatment in elderly patients with relapsed and refractory multiple myeloma. Hematology. 2017;22:88-92 pubmed publisher

Chen P, Li J, Chen Y, Qian H, Chen Y, Su J, et al. The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells. Cell Oncol (Dordr). 2016;39:511-522 pubmed

Boukes G, van de Venter M. The apoptotic and autophagic properties of two natural occurring prodrugs, hyperoside and hypoxoside, against pancreatic cancer cell lines. Biomed Pharmacother. 2016;83:617-626 pubmed publisher

Cook G, Ashcroft A, Cairns D, Williams C, Brown J, Cavenagh J, et al. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol. 2016;3:e340-51 pubmed publisher

Cecchin D, Negri A, Frigo A, Bui F, Zucchetta P, Bodanza V, et al. Calculating regional tissue volume for hyperthermic isolated limb perfusion: Four methods compared. Eur J Surg Oncol. 2016;42:1898-1905 pubmed publisher

Ferroudj S, Yildiz G, Bouras M, Iscan E, Ekin U, Ozturk M. Role of Fanconi anemia/BRCA pathway genes in hepatocellular carcinoma chemoresistance. Hepatol Res. 2016;46:1264-1274 pubmed publisher

Lub S, Maes A, Maes K, De Veirman K, De Bruyne E, Menu E, et al. Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells. Oncotarget. 2016;7:4062-76 pubmed publisher

Ramachandran I, Condamine T, Lin C, Herlihy S, Garfall A, Vogl D, et al. Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy. Cancer Lett. 2016;371:117-24 pubmed publisher

Lawson M, McDonald M, Kovacic N, Hua Khoo W, Terry R, Down J, et al. Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nat Commun. 2015;6:8983 pubmed publisher

Ben Shabat I, Belgrano V, Ny L, Nilsson J, Lindnér P, Olofsson Bagge R. Long-Term Follow-Up Evaluation of 68 Patients with Uveal Melanoma Liver Metastases Treated with Isolated Hepatic Perfusion. Ann Surg Oncol. 2016;23:1327-34 pubmed publisher

Ramani V, Zhan F, He J, Barbieri P, Noseda A, Tricot G, et al. Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma. Oncotarget. 2016;7:1598-607 pubmed publisher

Hughes M, Zager J, Faries M, Alexander H, Royal R, Wood B, et al. Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases. Ann Surg Oncol. 2016;23:1309-19 pubmed publisher

Legenzov E, Sims S, Dirda N, Rosen G, Kao J. Disulfide-Linked Dinitroxides for Monitoring Cellular Thiol Redox Status through Electron Paramagnetic Resonance Spectroscopy. Biochemistry. 2015;54:6973-82 pubmed publisher

Zhao J, Chu Z, Hu Y, Lin J, Wang Z, Jiang M, et al. Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma. Cancer Res. 2015;75:4384-4397 pubmed publisher

Nishihara K, Huang R, Zhao J, Shahane S, Witt K, Smith Roe S, et al. Identification of genotoxic compounds using isogenic DNA repair deficient DT40 cell lines on a quantitative high throughput screening platform. Mutagenesis. 2016;31:69-81 pubmed publisher

Hanley P, Melenhorst J, Nikiforow S, Scheinberg P, Blaney J, Demmler Harrison G, et al. CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo. Sci Transl Med. 2015;7:285ra63 pubmed publisher

Scarselli A, Di Cesare S, Capponi C, Cascioli S, Romiti M, Di Matteo G, et al. Longitudinal Evaluation of Immune Reconstitution and B-cell Function After Hematopoietic Cell Transplantation for Primary Immunodeficiency. J Clin Immunol. 2015;35:373-83 pubmed publisher

Suzuki S, Aihara Y, Fujiwara M, Sano S, Kaneko A. Intravitreal injection of melphalan for intraocular retinoblastoma. Jpn J Ophthalmol. 2015;59:164-72 pubmed publisher

Zub K, Sousa M, Sarno A, Sharma A, Demirovic A, Rao S, et al. Modulation of cell metabolic pathways and oxidative stress signaling contribute to acquired melphalan resistance in multiple myeloma cells. PLoS ONE. 2015;10:e0119857 pubmed publisher

Dudek Perić A, Ferreira G, Muchowicz A, Wouters J, Prada N, Martin S, et al. Antitumor immunity triggered by melphalan is potentiated by melanoma cell surface-associated calreticulin. Cancer Res. 2015;75:1603-14 pubmed publisher

Ngwube A, Hayashi R, Murray L, Loechelt B, Dalal J, Jaroscak J, et al. Alemtuzumab based reduced intensity transplantation for pediatric severe aplastic anemia. Pediatr Blood Cancer. 2015;62:1270-6 pubmed publisher

Asada H, Tomiyasu H, Goto Koshino Y, Fujino Y, Ohno K, Tsujimoto H. Evaluation of the drug sensitivity and expression of 16 drug resistance-related genes in canine histiocytic sarcoma cell lines. J Vet Med Sci. 2015;77:677-84 pubmed publisher

Xu H, He J, Zhang Y, Fan L, Zhao Y, Xu T, et al. Synthesis and in vitro evaluation of a hyaluronic acid-quantum dots-melphalan conjugate. Carbohydr Polym. 2015;121:132-9 pubmed publisher

Lombardi A, Hoskins E, Foglesong G, Wikenheiser Brokamp K, Wiesmüller L, Hanenberg H, et al. Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers. Clin Cancer Res. 2015;21:1962-72 pubmed publisher

Tamargo J, Caballero R, Delpón E. Cancer chemotherapy and cardiac arrhythmias: a review. Drug Saf. 2015;38:129-52 pubmed publisher

Lu X, Ding Z, Cao Y, Liu C, Habtetsion T, Yu M, et al. Alkylating agent melphalan augments the efficacy of adoptive immunotherapy using tumor-specific CD4+ T cells. J Immunol. 2015;194:2011-21 pubmed publisher

Beider K, Bitner H, Leiba M, Gutwein O, Koren Michowitz M, Ostrovsky O, et al. Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype. Oncotarget. 2014;5:11283-96 pubmed

Ongaro A, Pellati A, De Mattei M, de Terlizzi F, Rossi C, Campana L. Enhancement of melphalan activity by buthionine sulfoximine and electroporation in melanoma cells. Anticancer Drugs. 2015;26:284-92 pubmed publisher

Lawson B, Saktanasate J, Say E, Shields C. Intravitreal chemotherapy provides control for massive vitreous seeding from retinoblastoma. J Pediatr Ophthalmol Strabismus. 2014;51 Online:e92-4 pubmed publisher

Gertz M. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment. Am J Hematol. 2014;89:1132-40 pubmed publisher

Cioch M, Jawniak D, Kotwica K, Wach M, Mańko J, Gorący A, et al. Biosimilar granulocyte colony-stimulating factor is effective in reducing the duration of neutropenia after autologous peripheral blood stem cell transplantation. Transplant Proc. 2014;46:2882-4 pubmed publisher

Voermans N, Benveniste O, Minnema M, Lokhorst H, Lammens M, Meersseman W, et al. Sporadic late-onset nemaline myopathy with MGUS: long-term follow-up after melphalan and SCT. Neurology. 2014;83:2133-9 pubmed publisher

Dahan A, Wolk O, Yang P, Mittal S, Wu Z, Landowski C, et al. Dipeptidyl peptidase IV as a potential target for selective prodrug activation and chemotherapeutic action in cancers. Mol Pharm. 2014;11:4385-94 pubmed publisher

Song X, Kim S, Zhang L, Tang D, Bartlett D, Kwon Y, et al. Role of AMP-activated protein kinase in cross-talk between apoptosis and autophagy in human colon cancer. Cell Death Dis. 2014;5:e1504 pubmed publisher

Xiong T, Wei H, Chen X, Xiao H. PJ34, a poly(ADP-ribose) polymerase (PARP) inhibitor, reverses melphalan-resistance and inhibits repair of DNA double-strand breaks by targeting the FA/BRCA pathway in multidrug resistant multiple myeloma cell line RPMI8226/R. Int J Oncol. 2015;46:223-32 pubmed publisher

van Broekhoven D, Deroose J, Bonvalot S, Gronchi A, Grunhagen D, Eggermont A, et al. Isolated limb perfusion using tumour necrosis factor α and melphalan in patients with advanced aggressive fibromatosis. Br J Surg. 2014;101:1674-80 pubmed publisher

Avigan D, Rosenblatt J. Current treatment for multiple myeloma. N Engl J Med. 2014;371:961-2 pubmed publisher

Benboubker L, Dimopoulos M, Dispenzieri A, Catalano J, Belch A, Cavo M, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371:906-17 pubmed publisher

Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci M, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371:895-905 pubmed publisher

Yamada A, Moritake H, Kamimura S, Yamashita S, Takeshima H, Nunoi H. Proposed strategy for the use of high-dose chemotherapy with stem cell rescue and intrathecal topotecan without whole-brain irradiation for infantile classic medulloblastoma. Pediatr Blood Cancer. 2014;61:2316-8 pubmed publisher

Palladini G, Milani P, Foli A, Vidus Rosin M, Basset M, Lavatelli F, et al. Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients. Leukemia. 2014;28:2311-6 pubmed publisher

Hamouda M, Belhacene N, Puissant A, Colosetti P, Robert G, Jacquel A, et al. The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells. Oncotarget. 2014;5:6252-66 pubmed

Tagde A, Singh H, Kang M, Reynolds C. The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma. Blood Cancer J. 2014;4:e229 pubmed publisher

Rancea M, Will A, Borchmann P, Monsef I, Engert A, Skoetz N. Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma. J Natl Cancer Inst. 2014;106: pubmed publisher

Pencavel T, Wilkinson M, Mansfield D, Khan A, Seth R, Karapanagiotou E, et al. Isolated limb perfusion with melphalan, tumour necrosis factor-alpha and oncolytic vaccinia virus improves tumour targeting and prolongs survival in a rat model of advanced extremity sarcoma. Int J Cancer. 2015;136:965-76 pubmed publisher

Rytelewski M, Tong J, Buensuceso A, Leong H, Maleki Vareki S, Figueredo R, et al. BRCA2 inhibition enhances cisplatin-mediated alterations in tumor cell proliferation, metabolism, and metastasis. Mol Oncol. 2014;8:1429-40 pubmed publisher

Huerta Yepez S, Liu H, Baritaki S, Del Lourdes Cebrera Muñoz M, Rivera Pazos C, Maldonado Valenzuela A, et al. Overexpression of Yin Yang 1 in bone marrow-derived human multiple myeloma and its clinical significance. Int J Oncol. 2014;45:1184-92 pubmed publisher

Peng M, Xie J, Ucher A, Stavnezer J, Cantor S. Crosstalk between BRCA-Fanconi anemia and mismatch repair pathways prevents MSH2-dependent aberrant DNA damage responses. EMBO J. 2014;33:1698-712 pubmed publisher

McCarthy P. Second transplant as a standard for multiple myeloma. Lancet Oncol. 2014;15:786-8 pubmed publisher

Cook G, Williams C, Brown J, Cairns D, Cavenagh J, Snowden J, et al. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-la. Lancet Oncol. 2014;15:874-85 pubmed publisher

Francis J, Schaiquevich P, Buitrago E, Del Sole M, Zapata G, Croxatto J, et al. Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a preclinical and clinical study. Ophthalmology. 2014;121:1810-7 pubmed publisher

Buckstein R, Kerbel R, Cheung M, Shaked Y, Chodirker L, Lee C, et al. Lenalidomide and metronomic melphalan for CMML and higher risk MDS: a phase 2 clinical study with biomarkers of angiogenesis. Leuk Res. 2014;38:756-63 pubmed publisher

Katodritou E, Terpos E, Symeonidis A, Pouli A, Kelaidi C, Kyrtsonis M, et al. Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients. Am J Hematol. 2014;89:803-8 pubmed publisher

Shankar A, Hayward J, Kirkwood A, McCarthy K, Hewitt M, Morland B, et al. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy. Br J Haematol. 2014;165:534-44 pubmed publisher

Vogl T, Zangos S, Scholtz J, Schmitt F, Paetzold S, Trojan J, et al. Chemosaturation with percutaneous hepatic perfusions of melphalan for hepatic metastases: experience from two European centers. Rofo. 2014;186:937-44 pubmed publisher

Kim J, Stein A, Tsai N, Schultheiss T, Palmer J, Liu A, et al. Extramedullary relapse following total marrow and lymphoid irradiation in patients undergoing allogeneic hematopoietic cell transplantation. Int J Radiat Oncol Biol Phys. 2014;89:75-81 pubmed publisher

Huang S, Lin C, Lin H, Yao M, Tang J, Wu S, et al. Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma. Ann Hematol. 2014;93:1371-80 pubmed publisher

Shields C, Manjandavida F, Lally S, Pieretti G, Arepalli S, Caywood E, et al. Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma. Ophthalmology. 2014;121:1453-60 pubmed publisher

Kolstad A, Laurell A, Jerkeman M, Grønbæk K, Elonen E, Räty R, et al. Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. Blood. 2014;123:2953-9 pubmed publisher

Turley R, Tokuhisa Y, Toshimitsu H, Lidsky M, Padussis J, Fontanella A, et al. Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma. Ann Surg. 2015;261:368-77 pubmed publisher

Jakob J, Tunn P, Hayes A, Pilz L, Nowak K, Hohenberger P. Oncological outcome of primary non-metastatic soft tissue sarcoma treated by neoadjuvant isolated limb perfusion and tumor resection. J Surg Oncol. 2014;109:786-90 pubmed publisher

Rasche L, Strifler S, Duell J, Rosenwald A, Buck A, Maeder U, et al. The lymphoma-like polychemotherapy regimen "Dexa-BEAM" in advanced and extramedullary multiple myeloma. Ann Hematol. 2014;93:1207-14 pubmed publisher

Kroon H, Huismans A, Kam P, Thompson J. Isolated limb infusion with melphalan and actinomycin D for melanoma: a systematic review. J Surg Oncol. 2014;109:348-51 pubmed publisher

Ray A, Tian Z, Das D, Coffman R, Richardson P, Chauhan D, et al. A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib. Leukemia. 2014;28:1716-24 pubmed publisher

Dertinger S, Phonethepswath S, Avlasevich S, Torous D, Mereness J, Cottom J, et al. Pig-a gene mutation and micronucleated reticulocyte induction in rats exposed to tumorigenic doses of the leukemogenic agents chlorambucil, thiotepa, melphalan, and 1,3-propane sultone. Environ Mol Mutagen. 2014;55:299-308 pubmed publisher

Nieweg O, Kroon B. Isolated limb perfusion with melphalan for melanoma. J Surg Oncol. 2014;109:332-7 pubmed publisher

Hoekstra H, Veerman K, van Ginkel R. Isolated limb perfusion for in-transit melanoma metastases: melphalan or TNF-melphalan perfusion?. J Surg Oncol. 2014;109:338-47 pubmed publisher

Kato K, Yoshida N, Matsumoto K, Matsuyama T. Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia. Pediatr Blood Cancer. 2014;61:712-6 pubmed publisher

Taich P, Ceciliano A, Buitrago E, Sampor C, Fandino A, Villasante F, et al. Clinical pharmacokinetics of intra-arterial melphalan and topotecan combination in patients with retinoblastoma. Ophthalmology. 2014;121:889-97 pubmed publisher

Steinman J, Ariyan C, Rafferty B, Brady M. Factors associated with response, survival, and limb salvage in patients undergoing isolated limb infusion. J Surg Oncol. 2014;109:405-9 pubmed publisher

Surget S, Lemieux Blanchard E, Maiga S, Descamps G, Le Gouill S, Moreau P, et al. Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other. Leuk Lymphoma. 2014;55:2165-73 pubmed publisher

Morabito F, Bringhen S, Larocca A, Wijermans P, Victoria Mateos M, Gimsing P, et al. Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. Am J Hematol. 2014;89:355-62 pubmed publisher

Bhatnagar B, Rapoport A, Fang H, Ilyas C, Marangoz D, Akbulut V, et al. Single center experience with total body irradiation and melphalan (TBI-MEL) myeloablative conditioning regimen for allogeneic stem cell transplantation (SCT) in patients with refractory hematologic malignancies. Ann Hematol. 2014;93:653-60 pubmed publisher

Valteau Couanet D, Le Deley M, Bergeron C, Ducassou S, Michon J, Rubie H, et al. Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy. Pediatr Blood Cancer. 2014;61:977-81 pubmed publisher

Sarici A, Kizilkilic O, Celkan T, Gode S. Blue toe syndrome as a complication of intra-arterial chemotherapy for retinoblastoma. JAMA Ophthalmol. 2013;131:801-2 pubmed publisher

Orabi M, Taniguchi S, Sakagami H, Yoshimura M, Yoshida T, Hatano T. Hydrolyzable tannins of tamaricaceous plants. V. Structures of monomeric-trimeric tannins and cytotoxicity of macrocyclic-type tannins isolated from Tamarix nilotica (1). J Nat Prod. 2013;76:947-56 pubmed publisher

Uzgare R, Sheets T, Johnston D. Evaluation of melphalan, oxaliplatin, and paclitaxel in colon, liver, and gastric cancer cell lines in a short-term exposure model of chemosaturation therapy by percutaneous hepatic perfusion. Anticancer Res. 2013;33:1989-2000 pubmed

Ara T, Nakata R, Sheard M, Shimada H, Buettner R, Groshen S, et al. Critical role of STAT3 in IL-6-mediated drug resistance in human neuroblastoma. Cancer Res. 2013;73:3852-64 pubmed publisher

Hernández Reyes J, Galo Hooker E, Ruiz Delgado G, Ruiz Arguelles G. Systemic immunoglobulin light-chain amyloidosis (AL) in Mexico: a single institution, 30-year experience. Rev Invest Clin. 2012;64:604-8 pubmed

Warren J, Harlan L, Stevens J, Little R, Abel G. Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States. J Clin Oncol. 2013;31:1984-9 pubmed publisher

Eroglu C, Kaynar L, Orhan O, Keklik M, Sahin C, Yildiz O, et al. Contribution of involved-field radiotherapy to survival in patients with relapsed or refractory Hodgkin lymphoma undergoing autologous stem cell transplantation. Am J Clin Oncol. 2015;38:68-73 pubmed publisher

Lidsky M, Turley R, Beasley G, Sharma K, Tyler D. Predicting disease progression after regional therapy for in-transit melanoma. JAMA Surg. 2013;148:493-8 pubmed publisher

Gencheva M, Hare I, Kurian S, Fortney J, Piktel D, WYSOLMERSKI R, et al. Bone marrow osteoblast vulnerability to chemotherapy. Eur J Haematol. 2013;90:469-78 pubmed publisher

Martino M, Olivieri A, Offidani M, Vigna E, Moscato T, Fedele R, et al. Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma. Expert Opin Investig Drugs. 2013;22:619-34 pubmed publisher

Mikesch J, Kuhlmann M, Demant A, Krug U, Thoennissen G, Schmidt E, et al. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center. Ann Hematol. 2013;92:1041-8 pubmed publisher

Scala C, Ortiz K, Nicolier A, Briend Marchal A. Lymphocytic leukemia in a captive dhole (Cuon alpinus). J Zoo Wildl Med. 2013;44:204-7 pubmed

Boschmans J, De Bruijn E, Van Schil P, Lemiere F. Analysis of novel melphalan hydrolysis products formed under isolated lung perfusion conditions using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2013;27:835-41 pubmed publisher

Gallerne C, Prola A, Lemaire C. Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2. Biochim Biophys Acta. 2013;1833:1356-66 pubmed publisher

Suzuki S, Yokota S, Masuyama T, Ogihara H, Ohishi M, Katayama N, et al. [Autopsy case of light chain deposition disease presented by nephrotic syndrome]. Nihon Jinzo Gakkai Shi. 2013;55:63-70 pubmed

Shetty G, Beasley G, Sparks S, Barfield M, Masoud M, Mosca P, et al. Plasma cytokine analysis in patients with advanced extremity melanoma undergoing isolated limb infusion. Ann Surg Oncol. 2013;20:1128-35 pubmed publisher

Deng L, Zhang J, Wu T, Lawrie T. Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour. Cochrane Database Syst Rev. 2013;:CD005196 pubmed publisher

Okuyama H, Yamaya H, Fukusima T, Yokoyama H. A patient with persistent renal AL amyloid deposition after clinical remission by HDM/SCT therapy. Clin Nephrol. 2013;79:233-6 pubmed

Fryer R, Graham T, Smith E, Walker Samuel S, Morgan G, Robinson S, et al. Characterization of a novel mouse model of multiple myeloma and its use in preclinical therapeutic assessment. PLoS ONE. 2013;8:e57641 pubmed publisher

Sousa M, Zub K, Aas P, Hanssen Bauer A, Demirovic A, Sarno A, et al. An inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cells. PLoS ONE. 2013;8:e55493 pubmed publisher

Li Y, Zhang J, Ma H, Chen X, Liu T, Jiao Z, et al. Protective role of autophagy in matrine?induced gastric cancer cell death. Int J Oncol. 2013;42:1417-26 pubmed publisher

Li J, Zhou D. New advances in the diagnosis and treatment of POEMS syndrome. Br J Haematol. 2013;161:303-15 pubmed publisher

Nizeica V, Collet P, Marotte H. Bortezomib induced a phrenic palsy in a multiple myeloma patient. Ann Hematol. 2013;92:1135-6 pubmed publisher

Bhangu A, Broom L, Nepogodiev D, Gourevitch D, Desai A. Outcomes of isolated limb perfusion in the treatment of extremity soft tissue sarcoma: a systematic review. Eur J Surg Oncol. 2013;39:311-9 pubmed publisher

Granstam S, Rosengren S, Vedin O, Kero T, Sorensen J, Carlson K, et al. Evaluation of patients with cardiac amyloidosis using echocardiography, ECG and right heart catheterization. Amyloid. 2013;20:27-33 pubmed publisher

Abruzzo T, Patino M, Leach J, Rahme R, Geller J. Cerebral vasoconstriction triggered by sympathomimetic drugs during intra-atrerial chemotherapy. Pediatr Neurol. 2013;48:139-42 pubmed publisher

Gorovoy I, Layer N, Kim H, Nobles S, Stewart P, Vagefi M, et al. Pilomatrixoma in a patient with bilateral retinoblastoma. J AAPOS. 2013;17:103-4 pubmed publisher

Bayraktar U, Bashir Q, Qazilbash M, Champlin R, Ciurea S. Fifty years of melphalan use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19:344-56 pubmed publisher

Defty C, Marsden J. Melphalan in regional chemotherapy for locally recurrent metastatic melanoma. Curr Top Med Chem. 2012;12:53-60 pubmed

Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W. Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). PLoS Comput Biol. 2011;7:e1002310 pubmed publisher

Bringmann G, Zhang G, Hager A, Moos M, Irmer A, Bargou R, et al. Anti-tumoral activities of dioncoquinones B and C and related naphthoquinones gained from total synthesis or isolation from plants. Eur J Med Chem. 2011;46:5778-89 pubmed publisher

Yadav Y, Maclean E, Bhattacharyya A, Parmar V, Balzarini J, Barden C, et al. Design, synthesis and bioevaluation of novel candidate selective estrogen receptor modulators. Eur J Med Chem. 2011;46:3858-66 pubmed publisher

Das U, Pati H, Sakagami H, Hashimoto K, Kawase M, Balzarini J, et al. 3,5-Bis(benzylidene)-1-[3-(2-hydroxyethylthio)propanoyl]piperidin-4-ones: a novel cluster of potent tumor-selective cytotoxins. J Med Chem. 2011;54:3445-9 pubmed publisher

Scutaru A, Wenzel M, Gust R. Bivalent bendamustine and melphalan derivatives as anticancer agents. Eur J Med Chem. 2011;46:1604-15 pubmed publisher

Marvania B, Lee P, Chaniyara R, Dong H, Suman S, Kakadiya R, et al. Design, synthesis and antitumor evaluation of phenyl N-mustard-quinazoline conjugates. Bioorg Med Chem. 2011;19:1987-98 pubmed publisher

Romagnoli R, Baraldi P, Cruz Lopez O, Tolomeo M, Di Cristina A, Pipitone R, et al. Synthesis of novel antimitotic agents based on 2-amino-3-aroyl-5-(hetero)arylethynyl thiophene derivatives. Bioorg Med Chem Lett. 2011;21:2746-51 pubmed publisher

Demirayak S, Kayagil I, Yurttas L. Microwave supported synthesis of some novel 1,3-diarylpyrazino[1,2-a]benzimidazole derivatives and investigation of their anticancer activities. Eur J Med Chem. 2011;46:411-6 pubmed publisher

Krug M, Erlenkamp G, Sippl W, Schächtele C, Totzke F, Hilgeroth A. Discovery and selectivity-profiling of 4-benzylamino 1-aza-9-oxafluorene derivatives as lead structures for IGF-1R inhibitors. Bioorg Med Chem Lett. 2010;20:6915-9 pubmed publisher

Leonova E, Makarov M, Rybalkina E, Nayani S, Tongwa P, Fonari A, et al. Structure-cytotoxicity relationship in a series of N-phosphorus substituted E,E-3,5-bis(3-pyridinylmethylene)- and E,E-3,5-bis(4-pyridinylmethylene)piperid-4-ones. Eur J Med Chem. 2010;45:5926-34 pubmed publisher

Das S, Das U, Sakagami H, Hashimoto K, Kawase M, Gorecki D, et al. Sequential cytotoxicity: a theory examined using a series of 3,5-bis(benzylidene)-1-diethylphosphono-4-oxopiperidines and related phosphonic acids. Bioorg Med Chem Lett. 2010;20:6464-8 pubmed publisher

Oe Y, Nakaya I, Yahata M, Sakuma T, Sato H, Soma J. A case of γ1-heavy chain deposition disease successfully treated with melphalan and prednisolone therapy. Intern Med. 2010;49:1411-5 pubmed

Kam P, Thompson J. Isolated limb infusion with melphalan and actinomycin D in melanoma patients: factors predictive of acute regional toxicity. Expert Opin Drug Metab Toxicol. 2010;6:1039-45 pubmed publisher

Matharu J, Oki J, Worthen D, Smith Q, Crooks P. Regiospecific and conformationally restrained analogs of melphalan and DL-2-NAM-7 and their affinities for the large neutral amino acid transporter (system LAT1) of the blood-brain barrier. Bioorg Med Chem Lett. 2010;20:3688-91 pubmed publisher

Romagnoli R, Baraldi P, Cruz Lopez O, Lopez Cara C, Carrion M, Balzarini J, et al. Symmetrical alpha-bromoacryloylamido diaryldienone derivatives as a novel series of antiproliferative agents. Design, synthesis and biological evaluation. Bioorg Med Chem Lett. 2010;20:2733-9 pubmed publisher

Palumbo A, Davies F, Kropff M, Blade J, Delforge M, Leal da Costa F, et al. Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma. Ann Hematol. 2010;89:803-11 pubmed publisher

Das U, Doroudi A, Inci Gul H, Pati H, Kawase M, Sakagami H, et al. Cytotoxic 2-benzylidene-6-(nitrobenzylidene)cyclohexanones which display substantially greater toxicity for neoplasms than non-malignant cells. Bioorg Med Chem. 2010;18:2219-24 pubmed publisher

Prado Prado F, Garcia Mera X, González Díaz H. Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species. Bioorg Med Chem. 2010;18:2225-2231 pubmed publisher

Kakadiya R, Dong H, Kumar A, Narsinh D, Zhang X, Chou T, et al. Potent DNA-directed alkylating agents: Synthesis and biological activity of phenyl N-mustard-quinoline conjugates having a urea or hydrazinecarboxamide linker. Bioorg Med Chem. 2010;18:2285-2299 pubmed publisher

Jha A, Mukherjee C, Prasad A, Parmar V, Vadaparti M, Das U, et al. Derivatives of aryl amines containing the cytotoxic 1,4-dioxo-2-butenyl pharmacophore. Bioorg Med Chem Lett. 2010;20:1510-5 pubmed publisher

Toropov A, Toropova A, Raska I, Benfenati E. QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations. Eur J Med Chem. 2010;45:1639-47 pubmed publisher

Das U, Sakagami H, Chu Q, Wang Q, Kawase M, Selvakumar P, et al. 3,5-Bis(benzylidene)-1-[4-2-(morpholin-4-yl)ethoxyphenylcarbonyl]-4-piperidone hydrochloride: a lead tumor-specific cytotoxin which induces apoptosis and autophagy. Bioorg Med Chem Lett. 2010;20:912-7 pubmed publisher

Kruhlak N, Choi S, Contrera J, Weaver J, Willard J, Hastings K, et al. Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. Toxicol Mech Methods. 2008;18:217-27 pubmed publisher

Fourches D, Barnes J, Day N, Bradley P, Reed J, Tropsha A. Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chem Res Toxicol. 2010;23:171-83 pubmed publisher

Makarov M, Leonova E, Rybalkina E, Tongwa P, Khrustalev V, Timofeeva T, et al. Synthesis, characterization and structure-activity relationship of novel N-phosphorylated E,E-3,5-bis(thienylidene)piperid-4-ones. Eur J Med Chem. 2010;45:992-1000 pubmed publisher

Tam K, Avdeef A, Tsinman O, Sun N. The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem. 2010;53:392-401 pubmed publisher

Youssef D, Potter E, Jha M, De Clercq E, Balzarini J, Stables J, et al. Design, synthesis and bioevaluation of novel maleamic amino acid ester conjugates of 3,5-bisarylmethylene-4-piperidones as cytostatic agents. Bioorg Med Chem Lett. 2009;19:6364-7 pubmed publisher

Yuan J, Johnson R, Huang R, Wichterman J, Jiang H, Hayton K, et al. Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum. Nat Chem Biol. 2009;5:765-71 pubmed publisher

Varma M, Feng B, Obach R, Troutman M, Chupka J, Miller H, et al. Physicochemical determinants of human renal clearance. J Med Chem. 2009;52:4844-52 pubmed publisher

Das U, Pati H, Panda A, De Clercq E, Balzarini J, Molnar J, et al. 2-(3-Aryl-2-propenoyl)-3-methylquinoxaline-1,4-dioxides: a novel cluster of tumor-specific cytotoxins which reverse multidrug resistance. Bioorg Med Chem. 2009;17:3909-15 pubmed publisher

Grünhagen D, de Wilt J, van Geel A, Verhoef C, Eggermont A. Isolated limb perfusion with TNF-alpha and melphalan in locally advanced soft tissue sarcomas of the extremities. Recent Results Cancer Res. 2009;179:257-70 pubmed

Makarov M, Rybalkina E, Röschenthaler G, Short K, Timofeeva T, Odinets I. Design, cytotoxic and fluorescent properties of novel N-phosphorylalkyl substituted E,E-3,5-bis(arylidene)piperid-4-ones. Eur J Med Chem. 2009;44:2135-44 pubmed publisher

Santana L, González Díaz H, Quezada E, Uriarte E, Yáñez M, Viña D, et al. Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem. 2008;51:6740-51 pubmed publisher

Pati H, Das U, Das S, Bandy B, De Clercq E, Balzarini J, et al. The cytotoxic properties and preferential toxicity to tumour cells displayed by some 2,4-bis(benzylidene)-8-methyl-8-azabicyclo[3.2.1] octan-3-ones and 3,5-bis(benzylidene)-1-methyl-4-piperidones. Eur J Med Chem. 2009;44:54-62 pubmed publisher

Das U, Doroudi A, Das S, Bandy B, Balzarini J, De Clercq E, et al. E,E-2-Benzylidene-6-(nitrobenzylidene)cyclohexanones: syntheses, cytotoxicity and an examination of some of their electronic, steric, and hydrophobic properties. Bioorg Med Chem. 2008;16:6261-8 pubmed publisher

Kapuriya N, Kapuriya K, Zhang X, Chou T, Kakadiya R, Wu Y, et al. Synthesis and biological activity of stable and potent antitumor agents, aniline nitrogen mustards linked to 9-anilinoacridines via a urea linkage. Bioorg Med Chem. 2008;16:5413-23 pubmed publisher

Obach R, Lombardo F, Waters N. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos. 2008;36:1385-405 pubmed publisher

Pati H, Das U, Kawase M, Sakagami H, Balzarini J, De Clercq E, et al. 1-Aryl-2-dimethylaminomethyl-2-propen-1-one hydrochlorides and related adducts: A quest for selective cytotoxicity for malignant cells. Bioorg Med Chem. 2008;16:5747-53 pubmed publisher

Padussis J, Steerman S, Tyler D, Mosca P. Pharmacokinetics & drug resistance of melphalan in regional chemotherapy: ILP versus ILI. Int J Hyperthermia. 2008;24:239-49 pubmed publisher

Taeger G, Grabellus F, Podleska L, Muller S, Ruchholtz S. Effectiveness of regional chemotherapy with TNF-alpha/melphalan in advanced soft tissue sarcoma of the extremities. Int J Hyperthermia. 2008;24:193-203 pubmed publisher

Saczewski F, Stencel A, Bieńczak A, Langowska K, Michaelis M, Werel W, et al. Structure-activity relationships of novel heteroaryl-acrylonitriles as cytotoxic and antibacterial agents. Eur J Med Chem. 2008;43:1847-57 pubmed publisher

Sivaramakrishnan S, Gates K. Possible chemical mechanisms underlying the antitumor activity of S-deoxyleinamycin. Bioorg Med Chem Lett. 2008;18:3076-80 pubmed

Verhoef C, de Wilt J, Grunhagen D, van Geel A, ten Hagen T, Eggermont A. Isolated limb perfusion with melphalan and TNF-alpha in the treatment of extremity sarcoma. Curr Treat Options Oncol. 2007;8:417-27 pubmed

Sanchorawala V, Seldin D. An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis. Amyloid. 2007;14:261-9 pubmed

Moda T, Montanari C, Andricopulo A. Hologram QSAR model for the prediction of human oral bioavailability. Bioorg Med Chem. 2007;15:7738-45 pubmed

Musto P, D Auria F. Melphalan: old and new uses of a still master drug for multiple myeloma. Expert Opin Investig Drugs. 2007;16:1467-87 pubmed

Perjesi P, Das U, De Clercq E, Balzarini J, Kawase M, Sakagami H, et al. Design, synthesis and antiproliferative activity of some 3-benzylidene-2,3-dihydro-1-benzopyran-4-ones which display selective toxicity for malignant cells. Eur J Med Chem. 2008;43:839-45 pubmed

Falco P, Bringhen S, Avonto I, Gay F, Morabito F, Boccadoro M, et al. Melphalan and its role in the management of patients with multiple myeloma. Expert Rev Anticancer Ther. 2007;7:945-57 pubmed

Stanchev S, Momekov G, Jensen F, Manolov I. Synthesis, computational study and cytotoxic activity of new 4-hydroxycoumarin derivatives. Eur J Med Chem. 2008;43:694-706 pubmed

Jha A, Mukherjee C, Prasad A, Parmar V, Clercq E, Balzarini J, et al. E,E,E-1-(4-Arylamino-4-oxo-2-butenoyl)-3,5-bis(arylidene)-4-piperidones: a topographical study of some novel potent cytotoxins. Bioorg Med Chem. 2007;15:5854-65 pubmed

Pati H, Das U, Quail J, Kawase M, Sakagami H, Dimmock J. Cytotoxic 3,5-bis(benzylidene)piperidin-4-ones and N-acyl analogs displaying selective toxicity for malignant cells. Eur J Med Chem. 2008;43:1-7 pubmed

Diamandis P, Wildenhain J, Clarke I, Sacher A, Graham J, Bellows D, et al. Chemical genetics reveals a complex functional ground state of neural stem cells. Nat Chem Biol. 2007;3:268-73 pubmed

Sagi A, Segal E, Satchi Fainaro R, Shabat D. Remarkable drug-release enhancement with an elimination-based AB3 self-immolative dendritic amplifier. Bioorg Med Chem. 2007;15:3720-7 pubmed

Das U, Kawase M, Sakagami H, Ideo A, Shimada J, Molnar J, et al. 3-(3,4,5-Trimethoxyphenyl)-1-oxo-2-propene: a novel pharmacophore displaying potent multidrug resistance reversal and selective cytotoxicity. Bioorg Med Chem. 2007;15:3373-80 pubmed

Piver M. Treatment of ovarian cancer at the crossroads: 50 years after single-agent melphalan chemotherapy. Oncology (Williston Park). 2006;20:1156, 1158 pubmed

Das U, Alcorn J, Shrivastav A, Sharma R, De Clercq E, Balzarini J, et al. Design, synthesis and cytotoxic properties of novel 1-[4-(2-alkylaminoethoxy)phenylcarbonyl]-3,5-bis(arylidene)-4-piperidones and related compounds. Eur J Med Chem. 2007;42:71-80 pubmed

Mohler M, Kang G, Hong S, Patil R, Kirichenko O, Li W, et al. Discovery of antiglioma activity of biaryl 1,2,3,4-tetrahydroisoquinoline derivatives and conformationally flexible analogues. J Med Chem. 2006;49:5845-8 pubmed

Bohm L. Inhibition of homologous recombination repair with Pentoxifylline targets G2 cells generated by radiotherapy and induces major enhancements of the toxicity of cisplatin and melphalan given after irradiation. Radiat Oncol. 2006;1:12 pubmed

Leung N, Dispenzieri A, Fervenza F, Lacy M, Villicana R, Cavalcante J, et al. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis. Am J Kidney Dis. 2005;46:270-7 pubmed

Ott I, Schmidt K, Kircher B, Schumacher P, Wiglenda T, Gust R. Antitumor-active cobalt-alkyne complexes derived from acetylsalicylic acid: studies on the mode of drug action. J Med Chem. 2005;48:622-9 pubmed

Lens M, Dawes M. Isolated limb perfusion with melphalan in the treatment of malignant melanoma of the extremities: a systematic review of randomised controlled trials. Lancet Oncol. 2003;4:359-64 pubmed

Bauer G, Povirk L. Specificity and kinetics of interstrand and intrastrand bifunctional alkylation by nitrogen mustards at a G-G-C sequence. Nucleic Acids Res. 1997;25:1211-8 pubmed

Orlandi L, Zaffaroni N, Bearzatto A, Silvestrini R. Effect of melphalan and hyperthermia on p34cdc2 kinase activity in human melanoma cells. Br J Cancer. 1996;74:1924-8 pubmed

Nawata S, Abecasis N, Ross H, Abolhoda A, Cheng H, Sachar K, et al. Isolated lung perfusion with melphalan for the treatment of metastatic pulmonary sarcoma. J Thorac Cardiovasc Surg. 1996;112:1542-7; discussion 1547-8 pubmed